Chemomab (Nasdaq:CMMB) is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in two Phase 2 clinical trials—one in primary sclerosing cholangitis and the second in liver fibrosis, with a Phase 2 trial in systemic sclerosis expected to begin in 2022.